1. Home
  2. MOLN

MOLN

Molecular Partners AG

Logo Molecular Partners AG

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Founded: 2004 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 133.0M IPO Year: 2021
Target Price: $4.50 AVG Volume (30 days): 3.1K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.07 EPS Growth: N/A
52 Week Low/High: $3.35 - $7.32 Next Earning Date: 03-14-2024
Revenue: $8,378,571 Revenue Growth: -96.29%
Revenue Growth (this year): 189.86% Revenue Growth (next year): -37.50%

Share on Social Networks: